CEP85

Summary

CEP85 (centrosomal protein 85, HGNC:25309) is a protein-coding gene on chromosome 1p36.11, encoding Centrosomal protein of 85 kDa (Q6P2H3). Acts as a regulator of centriole duplication through a direct interaction with STIL, a key factor involved in the early steps of centriole formation. It is a selective cancer dependency (DepMap: 30.1% of cell lines).

This gene encodes a protein that belongs to the centrosome-associated family of proteins. The centrosome is a subcellular organelle in the animal cell that functions as a microtubule organizing center and is involved in cell-cycle progression. Alternate splicing results in multiple transcript variants.

Source: NCBI Gene 64793 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 127 total
• Cancer dependency (DepMap): dependent in 30.1% of screened cell lines
• MANE Select transcript: NM_001319944

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25309
Approved symbol	CEP85
Name	centrosomal protein 85
Location	1p36.11
Locus type	gene with protein product
Status	Approved
Aliases	DKFZP434L0117
Ensembl gene	ENSG00000130695
Ensembl biotype	protein_coding
OMIM	618898
Entrez	64793

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 18 protein_coding, 4 protein_coding_CDS_not_defined

ENST00000252992, ENST00000451429, ENST00000453146, ENST00000468163, ENST00000469609, ENST00000480446, ENST00000491670, ENST00000640292, ENST00000861245, ENST00000861246, ENST00000861247, ENST00000861248, ENST00000861249, ENST00000928439, ENST00000928440, ENST00000928441, ENST00000928442, ENST00000928443, ENST00000928444, ENST00000928445, ENST00000928446, ENST00000942372

RefSeq mRNA: 4 — MANE Select: NM_001319944 NM_001281517, NM_001281518, NM_001319944, NM_022778

CCDS: CCDS277, CCDS60038, CCDS81285

Canonical transcript exons

ENST00000451429 — 14 exons

Exon	Start	End
ENSE00000896423	26268483	26268635
ENSE00001065297	26244166	26244318
ENSE00001065299	26255171	26255865
ENSE00001065306	26258143	26258260
ENSE00001065308	26257597	26257730
ENSE00001235611	26259617	26259802
ENSE00001634003	26277136	26278808
ENSE00001954842	26234200	26234310
ENSE00002185613	26239762	26239838
ENSE00003502005	26272021	26272071
ENSE00003512969	26276535	26276760
ENSE00003568237	26274964	26275071
ENSE00003581522	26271014	26271107
ENSE00003585107	26269460	26269614

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 96.65.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 16.6700 / max 215.0675, expressed in 1724 samples.

FANTOM5 promoters (5 alternative TSS)

Promoter ID	TPM avg	Samples expressed
1570	13.2423	1673
1569	3.1760	1245
1573	0.1044	26
1575	0.0906	23
1572	0.0566	24

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	96.65	gold quality
secondary oocyte	CL:0000655	96.64	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	95.76	gold quality
hindlimb stylopod muscle	UBERON:0004252	95.55	gold quality
diaphragm	UBERON:0001103	95.34	silver quality
gastrocnemius	UBERON:0001388	93.58	gold quality
vastus lateralis	UBERON:0001379	93.40	gold quality
apex of heart	UBERON:0002098	93.40	gold quality
muscle of leg	UBERON:0001383	93.26	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	93.15	gold quality
muscle organ	UBERON:0001630	93.09	gold quality
skeletal muscle organ	UBERON:0014892	93.09	gold quality
skeletal muscle tissue	UBERON:0001134	92.62	gold quality
quadriceps femoris	UBERON:0001377	92.50	gold quality
biceps brachii	UBERON:0001507	92.26	gold quality
triceps brachii	UBERON:0001509	91.65	gold quality
right testis	UBERON:0004534	91.39	gold quality
skeletal muscle tissue of biceps brachii	UBERON:0004502	90.93	gold quality
muscle tissue	UBERON:0002385	90.73	gold quality
left testis	UBERON:0004533	90.73	gold quality
heart left ventricle	UBERON:0002084	90.64	gold quality
cardiac ventricle	UBERON:0002082	90.34	gold quality
deltoid	UBERON:0001476	90.01	silver quality
sural nerve	UBERON:0015488	90.00	gold quality
testis	UBERON:0000473	89.66	gold quality
left ventricle myocardium	UBERON:0006566	89.36	gold quality
gluteal muscle	UBERON:0002000	88.27	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	87.65	gold quality
cardiac muscle of right atrium	UBERON:0003379	87.52	gold quality
heart	UBERON:0000948	86.97	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.67

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

89 targeting CEP85, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4534	99.99	66.58	1907
HSA-MIR-520G-5P	99.99	66.76	658
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-548AT-5P	99.96	70.83	2666
HSA-MIR-8082	99.95	67.27	1170
HSA-MIR-7845-5P	99.88	64.88	771
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-4428	99.73	66.41	1733
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-4516	99.61	67.78	3390
HSA-MIR-762	99.58	66.61	1994
HSA-MIR-6716-5P	99.56	68.62	1244
HSA-MIR-6727-3P	99.49	65.92	1333
HSA-MIR-4498	99.47	67.42	2360
HSA-MIR-3612	99.45	66.02	1333
HSA-MIR-650	99.45	65.77	1309
HSA-MIR-3915	99.45	68.49	1905
HSA-MIR-6165	99.44	67.12	1389

Functional genomics

DepMap (CRISPR cell-line fitness): dependent in 30.1% of screened cell lines.

Literature-anchored findings (GeneRIF, showing 3)

• Cep85 is a bona fide Nek2A-binding partner that surrounds the proximal ends of centrioles where it cooperates with PP1gamma (also known as PPP1CC) to antagonize Nek2A (PMID:26220856)
• Direct binding of CEP85 to STIL ensures robust PLK4 activation and efficient centriole assembly. (PMID:29712910)
• Direct interaction between CEP85 and STIL mediates PLK4-driven directed cell migration. (PMID:32107292)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	cep85	ENSDARG00000060215
mus_musculus	Cep85	ENSMUSG00000037443
rattus_norvegicus	Cep85	ENSRNOG00000016249

Paralogs (1): CEP85L (ENSG00000111860)

Protein

Protein identifiers

Centrosomal protein of 85 kDa — Q6P2H3 (reviewed: Q6P2H3)

Alternative names: Coiled-coil domain-containing protein 21

All UniProt accessions (2): Q6P2H3, H7BZW2

UniProt curated annotations — full annotation on UniProt →

Function. Acts as a regulator of centriole duplication through a direct interaction with STIL, a key factor involved in the early steps of centriole formation. The CEP85-STIL protein complex acts as a modulator of PLK4-driven cytoskeletal rearrangements and directional cell motility. Acts as a negative regulator of NEK2 to maintain the centrosome integrity in interphase. Suppresses centrosome disjunction by inhibiting NEK2 kinase activity.

Subunit / interactions. Homodimer. Interacts with STIL (via N-terminus); this interaction is essential for robust PLK4 activation and efficient centriole assembly and for PLK4-dependent cell migration. Interacts with PLK4; required for CEP85 to be able to drive centriole duplication and cell migration.

Subcellular location. Cytoplasm. Cytoskeleton. Microtubule organizing center. Centrosome. Spindle pole. Nucleus. Nucleolus. Centriole. Cell cortex.

Similarity. Belongs to the CEP85 family.

Isoforms (4)

UniProt ID	Names	Canonical?
Q6P2H3-1	1	yes
Q6P2H3-2	2
Q6P2H3-3	3
Q6P2H3-4	4

RefSeq proteins (3): NP_001268446, NP_001306873, NP_073615 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR040210	Cep85/Cep85L	Family
IPR058190	CC4_CEP85	Domain

Pfam: PF24555

UniProt features (30 total): region of interest 6, compositionally biased region 4, modified residue 4, sequence variant 4, splice variant 3, sequence conflict 3, mutagenesis site 2, coiled-coil region 2, chain 1, helix 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
5OI7	X-RAY DIFFRACTION	1.67
5OID	X-RAY DIFFRACTION	4.6

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q6P2H3-F1	68.09	0.33

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 17, 126, 141, 623

Mutagenesis-validated functional residues (2):

Position	Phenotype
640	strongly reduced interaction with stil. strongly reduced interaction with stil; when associated with a-644. does not aff
644	strongly reduced interaction with stil. strongly reduced interaction with stil; when associated with a-640. does not aff

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 190 (showing top): HORIUCHI_WTAP_TARGETS_DN, TGCGCANK_UNKNOWN, GOBP_REGULATION_OF_PHOSPHORYLATION, GOBP_NEGATIVE_REGULATION_OF_KINASE_ACTIVITY, CMYB_01, GOBP_REGULATION_OF_TRANSFERASE_ACTIVITY, GOCC_MICROTUBULE_ORGANIZING_CENTER, PATIL_LIVER_CANCER, MARTINEZ_RB1_TARGETS_UP, GOBP_CENTRIOLE_ASSEMBLY, GOBP_ORGANELLE_FISSION, GOBP_REGULATION_OF_CELL_CYCLE, GOBP_NEGATIVE_REGULATION_OF_PHOSPHORUS_METABOLIC_PROCESS, GOCC_CENTROSOME, GOBP_MITOTIC_NUCLEAR_DIVISION

GO Biological Process (6): negative regulation of protein kinase activity (GO:0006469), chromosome segregation (GO:0007059), centriole replication (GO:0007099), cell migration (GO:0016477), regulation of mitotic centrosome separation (GO:0046602), centriole assembly (GO:0098534)

GO Molecular Function (2): identical protein binding (GO:0042802), protein binding (GO:0005515)

GO Cellular Component (11): pericentriolar material (GO:0000242), spindle pole (GO:0000922), nucleolus (GO:0005730), Golgi apparatus (GO:0005794), centrosome (GO:0005813), centriole (GO:0005814), cytosol (GO:0005829), cell cortex (GO:0005938), nucleus (GO:0005634), cytoplasm (GO:0005737), cytoskeleton (GO:0005856)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
intracellular membraneless organelle	3
cytoplasm	3
cell cycle process	2
intracellular membrane-bounded organelle	2
microtubule organizing center	2
negative regulation of protein phosphorylation	1
protein kinase activity	1
negative regulation of kinase activity	1
regulation of protein kinase activity	1
centrosome duplication	1
centriole assembly	1
cell motility	1
mitotic centrosome separation	1
regulation of cell cycle process	1
microtubule organizing center organization	1
membraneless organelle assembly	1
protein binding	1
binding	1
centrosome	1
spindle	1
nuclear lumen	1
endomembrane system	1
centriole	1
cell periphery	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

890 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CEP85	STIL	Q15468	806
CEP85	CEP192	Q8TEP8	585
CEP85	RTTN	Q86VV8	564
CEP85	CCDC77	Q9BR77	549
CEP85	SASS6	Q6UVJ0	548
CEP85	PLK4	O00444	539
CEP85	CCDC150	Q8NCX0	534
CEP85	HAUS1	Q96CS2	528
CEP85	CEP131	Q9UPN4	505
CEP85	NEMP1	O14524	490
CEP85	REEP4	Q9H6H4	480
CEP85	CCDC34	Q96HJ3	471
CEP85	PDCD7	Q8N8D1	470
CEP85	GSTCD	Q8NEC7	459
CEP85	PCNT	O95613	450

IntAct

78 interactions, top by confidence:

A	B	Type	Score
SAV1	SEC16A	psi-mi:“MI:2364”(proximity)	0.570
CLEC11A	VWA8	psi-mi:“MI:0914”(association)	0.530
KCMF1	IDH2	psi-mi:“MI:0914”(association)	0.530
TERF1	CEP85	psi-mi:“MI:0915”(physical association)	0.510
CEP85		psi-mi:“MI:0915”(physical association)	0.510
	CEP85	psi-mi:“MI:0915”(physical association)	0.510
CEP85	MFHAS1	psi-mi:“MI:0407”(direct interaction)	0.440
Xpo1	IFT56	psi-mi:“MI:0914”(association)	0.350
EGLN3	FAM168B	psi-mi:“MI:0914”(association)	0.350
TRAF2	TMEM178B	psi-mi:“MI:0914”(association)	0.350
BMI1	HMGB1P1	psi-mi:“MI:0914”(association)	0.350
MIF	BLTP3B	psi-mi:“MI:0914”(association)	0.350
DUSP16	MEIOC	psi-mi:“MI:0914”(association)	0.350
NTAQ1	SBNO1	psi-mi:“MI:0914”(association)	0.350
CRYAA	TRIM24	psi-mi:“MI:0914”(association)	0.350
CEP85	SOX5	psi-mi:“MI:0914”(association)	0.350
C9orf163	ZSWIM8	psi-mi:“MI:0914”(association)	0.350
KCMF1	MDK	psi-mi:“MI:0914”(association)	0.350
KCMF1	CIT	psi-mi:“MI:0914”(association)	0.350
UBR4	METTL15	psi-mi:“MI:0914”(association)	0.350
OFD1	CCDC85C	psi-mi:“MI:2364”(proximity)	0.270
ODF2	DDX3X	psi-mi:“MI:2364”(proximity)	0.270
CEP128	CCDC66	psi-mi:“MI:2364”(proximity)	0.270
FBF1	CCDC85C	psi-mi:“MI:2364”(proximity)	0.270
RPGRIP1	IPO5	psi-mi:“MI:2364”(proximity)	0.270
SSX2IP	CCDC85C	psi-mi:“MI:2364”(proximity)	0.270
NINL	CCDC66	psi-mi:“MI:2364”(proximity)	0.270
OFD1	PSMD14	psi-mi:“MI:2364”(proximity)	0.270
CEP152	CNOT1	psi-mi:“MI:2364”(proximity)	0.270

BioGRID (231): CEP85 (Affinity Capture-RNA), CEP85 (Affinity Capture-RNA), CEP85 (Biochemical Activity), CEP85 (Affinity Capture-MS), CEP85 (Affinity Capture-MS), SOX13 (Affinity Capture-MS), SOX5 (Affinity Capture-MS), CEP44 (Affinity Capture-MS), CEP85 (Synthetic Growth Defect), CEP85 (Proximity Label-MS), CEP85 (Proximity Label-MS), CEP85 (Proximity Label-MS), CEP85 (Proximity Label-MS), CEP85 (Proximity Label-MS), CEP85 (Proximity Label-MS)

ESM2 similar proteins: A0A1L8GUX5, A0A1L8GXY6, A0A1W2P884, B8A5S6, E7F5E1, H2MTR9, O08970, O35711, O60296, P27628, P53564, P60853, Q0VF96, Q28GJ0, Q2KJD6, Q2TLZ3, Q3UIJ9, Q4V7D3, Q5BIX7, Q5R923, Q5SXA9, Q5SZL2, Q5U2Y9, Q5U4W1, Q5ZLT3, Q6AW69, Q6DIS8, Q6NRW2, Q6NXJ0, Q6P2H3, Q6P402, Q6PCQ0, Q6PD31, Q7TQE6, Q7TQG1, Q80ST9, Q86W92, Q8BMK0, Q8C8U0, Q8CFC9

Diamond homologs: A0A1W2P884, Q5SZL2, Q6P2H3, Q8BMK0

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
PLK1	“up-regulates activity”	CEP85	phosphorylation

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 88 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Loss of Nlp from mitotic centrosomes	9	29.1×	2e-09
Loss of proteins required for interphase microtubule organization from the centrosome	9	29.1×	2e-09
AURKA Activation by TPX2	9	28.0×	2e-09
Anchoring of the basal body to the plasma membrane	11	25.4×	1e-10
Recruitment of mitotic centrosome proteins and complexes	9	25.0×	5e-09
Regulation of PLK1 Activity at G2/M Transition	9	23.3×	7e-09
Recruitment of NuMA to mitotic centrosomes	9	21.4×	1e-08

GO biological processes:

GO term	Partners	Fold	FDR
centriole replication	6	61.1×	3e-07
smoothened signaling pathway	5	12.6×	5e-03
cilium assembly	7	7.2×	5e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

127 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	103
Likely benign	6
Benign	5

Top pathogenic / likely-pathogenic (0)

SpliceAI

3044 predictions. Top by Δscore:

Variant	Effect	Δscore
1:26244160:TTTCA:T	acceptor_loss	1.0000
1:26244161:TTCA:T	acceptor_loss	1.0000
1:26244162:TCAG:T	acceptor_loss	1.0000
1:26244163:CAGGT:C	acceptor_loss	1.0000
1:26244164:A:AG	acceptor_gain	1.0000
1:26244165:G:GG	acceptor_gain	1.0000
1:26244314:GGAGG:G	donor_gain	1.0000
1:26244315:GAGG:G	donor_gain	1.0000
1:26244315:GAGGG:G	donor_gain	1.0000
1:26244317:GG:G	donor_gain	1.0000
1:26244318:GG:G	donor_gain	1.0000
1:26244319:G:GG	donor_gain	1.0000
1:26244320:T:G	donor_loss	1.0000
1:26257688:G:GG	donor_gain	1.0000
1:26257731:G:GG	donor_gain	1.0000
1:26258140:CAGGC:C	acceptor_loss	1.0000
1:26258141:A:AG	acceptor_gain	1.0000
1:26258142:G:GA	acceptor_loss	1.0000
1:26258142:G:GG	acceptor_gain	1.0000
1:26258142:GGCA:G	acceptor_gain	1.0000
1:26258257:ACAGG:A	donor_loss	1.0000
1:26258259:AGGT:A	donor_loss	1.0000
1:26258261:G:GG	donor_gain	1.0000
1:26258262:T:A	donor_loss	1.0000
1:26259651:A:AG	acceptor_gain	1.0000
1:26259652:G:GG	acceptor_gain	1.0000
1:26259779:G:GT	donor_gain	1.0000
1:26259794:G:GT	donor_gain	1.0000
1:26259801:GG:G	donor_gain	1.0000
1:26259802:GG:G	donor_gain	1.0000

AlphaMissense

5000 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:26268565:G:C	R475P	1.000
1:26268583:G:C	R481P	1.000
1:26268589:T:C	L483P	0.999
1:26268598:T:C	L486P	0.999
1:26276683:T:C	L684P	0.999
1:26258166:T:C	L354P	0.998
1:26268492:C:A	R451S	0.998
1:26268493:G:C	R451P	0.998
1:26268591:G:C	A484P	0.998
1:26268564:C:A	R475S	0.997
1:26268577:T:C	L479S	0.997
1:26268585:T:G	Y482D	0.997
1:26258145:A:C	Q347P	0.996
1:26268581:G:C	E480D	0.996
1:26268581:G:T	E480D	0.996
1:26275060:G:C	A631P	0.996
1:26276746:T:C	L705P	0.996
1:26277211:T:C	L736P	0.996
1:26277236:G:C	R744S	0.996
1:26277236:G:T	R744S	0.996
1:26268518:A:C	K459N	0.995
1:26268518:A:T	K459N	0.995
1:26268585:T:C	Y482H	0.995
1:26268586:A:C	Y482S	0.995
1:26276536:T:C	L635P	0.995
1:26277259:C:A	A752D	0.995
1:26255237:C:A	A92D	0.994
1:26268586:A:G	Y482C	0.994
1:26276572:T:C	L647P	0.994
1:26276746:T:A	L705H	0.994

dbSNP variants (sampled 300 via entrez): RS1000028397 (1:26263419 G>T), RS1000048576 (1:26274528 T>C,G), RS1000074565 (1:26274872 C>A,G,T), RS1000188614 (1:26238874 T>G), RS1000271208 (1:26258445 AG>A), RS1000314227 (1:26262696 C>T), RS1000478838 (1:26256406 C>A), RS1000516629 (1:26233197 T>G), RS1000592514 (1:26268326 T>C), RS1000660554 (1:26268957 C>G,T), RS1000732938 (1:26274853 G>A,C), RS1000844643 (1:26250065 T>C), RS1000922794 (1:26270023 T>G), RS1000929424 (1:26251972 C>T), RS1000962761 (1:26268759 G>T)

Disease associations

OMIM: gene MIM:618898 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004608_2	Granulocyte percentage of myeloid white cells	2.000000e-11
GCST010043_81	Asthma	3.000000e-08
GCST90002382_65	Eosinophil percentage of white cells	2.000000e-12
GCST90002400_18	Plateletcrit	3.000000e-09

EFO canonical traits (3, from GWAS)

EFO ID	Trait name
EFO:0007997	granulocyte percentage of myeloid white cells
EFO:0007991	eosinophil percentage of leukocytes
EFO:0007985	platelet crit

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

41 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, increases abundance, increases expression	2
methacrylaldehyde	increases oxidation, increases abundance, affects cotreatment	2
Acrolein	affects cotreatment, increases oxidation, increases abundance	2
Ozone	affects cotreatment, increases oxidation, increases abundance	2
FR900359	affects phosphorylation	1
triphenyl phosphate	affects expression	1
alpha-pinene	increases oxidation, increases abundance, affects cotreatment	1
propionaldehyde	increases methylation	1
bisphenol A	affects cotreatment, increases methylation	1
nonanal	increases methylation	1
n-hexanal	increases methylation	1
butyraldehyde	increases methylation	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
caprylic aldehyde	increases methylation	1
pentanal	increases methylation	1
heptanal	increases methylation	1
perfluorooctane sulfonic acid	decreases expression	1
2,3,5-(triglutathion-S-yl)hydroquinone	increases ADP-ribosylation	1
ICG 001	increases expression	1
4-(4-((5-(4,5-dimethyl-2-nitrophenyl)-2-furanyl)methylene)-4,5-dihydro-3-methyl-5-oxo-1H-pyrazol-1-yl)benzoic acid	increases expression	1
Resveratrol	affects cotreatment, increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Leflunomide	decreases expression	1
Acetaminophen	increases expression	1
Air Pollutants	increases abundance, increases oxidation, affects cotreatment	1
Arsenic	decreases expression, increases abundance	1
Benzo(a)pyrene	affects methylation	1
Coumestrol	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Gasoline	affects cotreatment, decreases expression, increases abundance	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.